File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: FTY720, a fungus metabolite, inhibits invasion ability of androgen independent prostate cancer cells through inactivation of RhoA-GTPase

TitleFTY720, a fungus metabolite, inhibits invasion ability of androgen independent prostate cancer cells through inactivation of RhoA-GTPase
Authors
Issue Date2005
PublisherAmerican Association for Cancer Research
Citation
AACR 96th Annual Meeting, Anaheim CA, 16–20 April 2005. In Cancer Research, 2005, v. 65 n. 9S, p. 158 Abstract no. 669 How to Cite?
AbstractThe failure of controlling androgen-independent and metastatic prostate cancer growth is the main cause of death in prostate cancer patients. In this study, we have demonstrated a novel anticancer agent, FTY720, a fungus metabolite, in the suppression of metastatic ability of androgen independent prostate cancer cells. First, using colony forming assay, we found that FTY720 treatment led to decreased colony forming ability of androgen-independent prostate cancer cell lines DU145 and PC3, indicating its negative role on cancer cell survival. In addition, treatment with relatively low dose of FTY720 (i.e. Inhibitory Concentration of 50% cell survival) resulted in suppression of prostate cancer cell migration and invasion abilities demonstrated by Wound closure assay, 3-D collagen gel invasion assays and stress fiber staining. Furthermore, we found that the inhibitory effect of FTY720 on prostate cancer invasion was associated with down-regulation of GTP-bound active form of RhoA. Transfection of a dominant-active RhoA vector in DU145 and PC3 cells conferred resistance to FTY720-induced suppression of cell motility. These results indicate that FTY720 may be a potential effective agent against androgen independent prostate cancer. Since activation of RhoA-GTPase is associated with metastasis in many types of malignancies, our results not only suggest a new agent for the treatment of advanced prostate cancer, but also implicate a possible novel anti-cancer drug especially against metastatic cancers.
Persistent Identifierhttp://hdl.handle.net/10722/95037
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorZhou, Cen_HK
dc.contributor.authorLing, MTen_HK
dc.contributor.authorLee, TKWen_HK
dc.contributor.authorMan, Ken_HK
dc.contributor.authorWang, Xen_HK
dc.contributor.authorWong, YCen_HK
dc.date.accessioned2010-09-25T15:49:40Z-
dc.date.available2010-09-25T15:49:40Z-
dc.date.issued2005en_HK
dc.identifier.citationAACR 96th Annual Meeting, Anaheim CA, 16–20 April 2005. In Cancer Research, 2005, v. 65 n. 9S, p. 158 Abstract no. 669en_HK
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/95037-
dc.description.abstractThe failure of controlling androgen-independent and metastatic prostate cancer growth is the main cause of death in prostate cancer patients. In this study, we have demonstrated a novel anticancer agent, FTY720, a fungus metabolite, in the suppression of metastatic ability of androgen independent prostate cancer cells. First, using colony forming assay, we found that FTY720 treatment led to decreased colony forming ability of androgen-independent prostate cancer cell lines DU145 and PC3, indicating its negative role on cancer cell survival. In addition, treatment with relatively low dose of FTY720 (i.e. Inhibitory Concentration of 50% cell survival) resulted in suppression of prostate cancer cell migration and invasion abilities demonstrated by Wound closure assay, 3-D collagen gel invasion assays and stress fiber staining. Furthermore, we found that the inhibitory effect of FTY720 on prostate cancer invasion was associated with down-regulation of GTP-bound active form of RhoA. Transfection of a dominant-active RhoA vector in DU145 and PC3 cells conferred resistance to FTY720-induced suppression of cell motility. These results indicate that FTY720 may be a potential effective agent against androgen independent prostate cancer. Since activation of RhoA-GTPase is associated with metastasis in many types of malignancies, our results not only suggest a new agent for the treatment of advanced prostate cancer, but also implicate a possible novel anti-cancer drug especially against metastatic cancers.-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research-
dc.relation.ispartofCancer Researchen_HK
dc.titleFTY720, a fungus metabolite, inhibits invasion ability of androgen independent prostate cancer cells through inactivation of RhoA-GTPaseen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLing, MT: patling@HKUCC.hku.hken_HK
dc.identifier.emailMan, K: kwanman@hkucc.hku.hken_HK
dc.identifier.emailWong, YC: ycwong@hkucc.hku.hken_HK
dc.identifier.authorityLing, MT=rp00449en_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityWong, YC=rp00316en_HK
dc.identifier.hkuros98009en_HK
dc.identifier.volume65en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats